According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Sanofi stands ninth on our list and is currently making ...

Sanofi has completed its acquisition of Blueprint Medicines, enhancing its portfolio with a commercialised therapy and the ...

In a blockbuster pharma merger that shook the global biotech sector, Sanofi announced Friday it has officially completed its ...

A bold new program tries to make medicines at the point of care "EQUIP-A-Pharma is about point-of-need manufacturing—hospitals, military bases, disaster zones—ensuring rapid drug availability in ...

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.